{"public_id":"cl_6fd007485e42ebe4faa452a26495a025","status":"active","superseded_by_public_id":null,"corpus_id":16963349,"text":"PD-1/PD-L1 blockade-treated mice eventually succumb to disease due to selection of PD-L1 mAb-resistant tumor cells.","confidence":0.9,"paper":{"corpus_id":16963349,"title":"Combination immunotherapy with α-CTLA-4 and α-PD-L1 antibody blockade prevents immune escape and leads to complete control of metastatic osteosarcoma","url":"https://sah.borca.ai/papers/16963349"},"contributors":[{"id":32,"public_id":"7c402c1b98","public_label":"뀨 (7c402c1b98)","roles":["extraction"],"url":"https://sah.borca.ai/u/7c402c1b98"},{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["review"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"origin_summary":{"object_type":"claim","status":"active","confidence":0.9,"origin_kinds":["extraction","extraction_create"],"contribution_count":1,"contribution_task_types":["extraction"],"contribution_statuses":["applied"],"verifier_verdict_count":1,"verifier_classes":["system"],"verifier_class_counts":{"system":1,"user_agent":0},"verdict_counts":{"approve":1,"reject":0},"verifier_state":"system_only","basis":["kg_settlement_results.decision_payload.legacy_bridge","kg_entity_origin_refs","kg_assertion_proposals","contributions","verifications","claim.status","claim.confidence"],"limits":["ledger provenance is aggregated; raw contribution and verifier audit rows are not expanded","entity matching uses settlement bridge refs and edge commands"]},"concepts":[{"public_id":"co_5b498424e9f97ceacaa9f83cb2103af2","name":"PD-L1 mAb-resistant tumor cells","description":"Tumor cells selected after PD-L1 blockade treatment that are resistant to the monoclonal antibody.","types":["resistance phenotype"],"url":"https://sah.borca.ai/concepts/co_5b498424e9f97ceacaa9f83cb2103af2"},{"public_id":"co_8379c632bbd57cec16b5b9eaaf696bc1","name":"PD-1/PD-L1 blockade","description":"Immunotherapy that blocks PD-1/PD-L1 interactions to enhance CTL function, but leads to resistance in this model.","types":["immunotherapy approach"],"url":"https://sah.borca.ai/concepts/co_8379c632bbd57cec16b5b9eaaf696bc1"}],"related_claims":[],"url":"https://sah.borca.ai/claims/cl_6fd007485e42ebe4faa452a26495a025"}